Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Patent
1993-01-21
1995-04-04
Nucker, Christine M.
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
4241991, 435 693, 4351723, 4352351, A61K 3921, C12N 1548
Patent
active
054035821
ABSTRACT:
A recombinant fowlpox virus is provided which is useful as a vaccine for protection against avian reticuloendo-theliosis virus-associated diseases. In a specific embodiment, the recombinant virus expresses a gene encoding an envelope glycoprotein of spleen necrosis virus under the control of a poxvirus promoter, inserted in a nonessential region of the fowlpox virus genome.
REFERENCES:
patent: 5174993 (1992-12-01), Paoletti
patent: 5187087 (1993-02-01), Sondermeijer et al.
patent: 5208024 (1993-03-01), Van Den Bosch
Federspiel et al, Virology 173(1): 167-177, 1989.
Witter et al, Avian Diseases 33:226-235, 1989.
Earl et al, Science 234:728-731, 1986.
Fadly et al, Infection and Immunity 37(3):1156-1161, 1982.
Bennett et al, Virus Res 8(1) pp. 73-77, 1987.
Calvert Jay G.
Nazerian Keyvan
Witter Richard L.
Yanagida Noboru
Krsek-Staples Julie
Nippon Zeon Co. Ltd.
Nucker Christine M.
The United States of America as represented by the Secretary of
LandOfFree
Vaccine comprising fowlpox virus recombinants expressing the env does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Vaccine comprising fowlpox virus recombinants expressing the env, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vaccine comprising fowlpox virus recombinants expressing the env will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2379408